Skip to main content
Clinical Trials/NCT01679249
NCT01679249
Completed
Not Applicable

Blood Volume Analysis and Related Outcomes in Hemodialysis

VA New York Harbor Healthcare System1 site in 1 country10 target enrollmentJanuary 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
End Stage Kidney Disease
Sponsor
VA New York Harbor Healthcare System
Enrollment
10
Locations
1
Primary Endpoint
Blood volume measurement and comparison to Crit-Line reading
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

An understanding of fluid changes that occur during hemodialysis (HD) with ultrafiltration (UF) is essential for determining the efficacy of HD, as well as for reducing complications related to hypovolemia or, conversely, chronic volume overload.

Detailed Description

Background: Accurate assessment of the BV and distribution of body fluids is essential for prescribing HD and for reducing complications related to hypovolemia and volume overload. Monitoring relative changes in BV using hematocrit (Hct), e.g. CLM-III, an indirect method, cannot be used to determine the absolute levels of BV. Here we report the first study of isotope BV measurement (IBVM) for assessing volume status in HD patients using indicator dilutional method. 10 adult HD patients were enrolled in this prospective observational study. Multi-point IBVM before and after HD was performed using BVA-100 (Daxor, New York, NY). BVA-100 calculates BV with an accuracy of ±2.5%, by using \<25μCi of iodinated I-131 albumin. It assumes normal BV for a given individual on the basis of patients' deviation from ideal body weight. Fluid loss from the extravascular component of the extracellular space (EV) was calculated by subtracting absolute BV change from total weight loss. Intradialytic relative BV changes were measured by CLM-III during the same HD session. Bland-Altman plot was used to compare relative BV change pre- and post-HD by IBVM and CLM-III.

Registry
clinicaltrials.gov
Start Date
January 2012
End Date
May 2012
Last Updated
13 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
VA New York Harbor Healthcare System
Responsible Party
Principal Investigator
Principal Investigator

David S. Goldfarb, M.D.

Chief, Nephrology

VA New York Harbor Healthcare System

Eligibility Criteria

Inclusion Criteria

  • Age \>21 years
  • Primary diagnosis of either chronic or acute kidney disease
  • Currently receiving HD treatment
  • Thrice-weekly or twice-weekly HD schedule
  • Treated with standard bicarbonate HD for at least the preceding 6 months

Exclusion Criteria

  • Pregnant women or nursing mothers
  • Known hypersensitivity to iodine, eggs, albumin or any other component of the Volumex injection kit
  • Current enrollment in another investigational treatment protocol for dialysis
  • The need to perform hemodialysis with predilution because this will interfere with measurements of relative blood volume changes (ΔRBV)
  • Kidney transplantation
  • Malignancy requiring chemotherapy
  • Unmeasurable blood pressure with a sphygmomanometer
  • Active hematological disease
  • Active gastrointestinal bleeding
  • Severe malnutrition (predialysis serum albumin \<2.6 g/dL)

Outcomes

Primary Outcomes

Blood volume measurement and comparison to Crit-Line reading

Time Frame: Six months

To compare the results obtained by two different methods of assessing BV: direct measurement of BV using the Blood Volume Analyzer (BVA-100) vs. indirect measurement of relative changes in BV using the Crit-Line Monitor (CLM III). Blood volume is measured in liters and compared with "ideal blood volume" nomograms. Crit-Line Monitor measures relative change in blood volume as a percentage change and does not have absolute values.

Study Sites (1)

Loading locations...

Similar Trials